Literature DB >> 8504574

Progression of left ventricular enlargement in patients with hypertrophic cardiomyopathy: incidence and prognostic value.

K Hina1, S Kusachi, K Iwasaki, K Nogami, H Moritani, T Kita, G Taniguchi, T Tsuji.   

Abstract

A total of 51 patients with hypertrophic cardiomyopathy (HCM) were followed for at least 3 years (mean follow-up period 6.5 years) by serial M-mode and two-dimensional echocardiography. An increase of the left ventricular diastolic dimension (LVDd) to > or = 55 mm with a decrease in the left ventricular ejection fraction (LVEF) to < 55% was observed in eight (15.7%) patients (progressive disease group). In five of these eight patients, the LVDd was > or = 60 mm and the LVEF was < 40%. Ventricular enlargement was closely related to mortality and death due to congestive heart failure occurred in three of these patients. No deaths occurred among the 37 patients without significant progression of ventricular enlargement (nonprogressive group). The annual changes of LVEF and LVDd in the progressive disease group were larger than in the nonprogressive group (LVEF -0.18 +/- 1.45 vs. -2.46 +/- 1.47 %/year; LVDd 0.22 +/- 0.81 vs. 1.43 +/- 0.77 mm/year). An increment in LVDs occurred earlier than the enlargement of the LVDd. Therefore, close attention to the LVDs seems to be important to detect early left ventricular morphological changes in HCM. In summary, this study indicates that HCM patients include a subgroup with symptoms resembling dilated cardiomyopathy, in whom the left ventricle enlarges with hypofunction and in whom there is high mortality due to congestive heart failure.

Entities:  

Mesh:

Year:  1993        PMID: 8504574     DOI: 10.1002/clc.4960160507

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  8 in total

1.  Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy.

Authors:  R Thaman; J R Gimeno; R T Murphy; T Kubo; B Sachdev; J Mogensen; P M Elliott; W J McKenna
Journal:  Heart       Date:  2005-07       Impact factor: 5.994

2.  Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients.

Authors:  L Faber; A Meissner; P Ziemssen; H Seggewiss
Journal:  Heart       Date:  2000-03       Impact factor: 5.994

3.  Prognosis of hypertrophic cardiomyopathy: assessment by 123I-BMIPP (beta-methyl-p-(123I)iodophenyl pentadecanoic acid) myocardial single photon emission computed tomography.

Authors:  T Nishimura; S Nagata; T Uehara; T Morozumi; Y Ishida; T Nakata; O Iimura; C Kurata; Y Wakabayashi; H Sugihara; K Otsuki; T Wada; Y Koga
Journal:  Ann Nucl Med       Date:  1996-02       Impact factor: 2.668

4.  CMR assessment and clinical outcomes of hypertrophic cardiomyopathy with or without ventricular remodeling in the end-stage phase.

Authors:  Sainan Cheng; Yeon Hyeon Choe; Hideki Ota; Chen Cui; Gang Yin; Minjie Lu; Lu Li; Xiuyu Chen; Sanjay K Prasad; Shihua Zhao
Journal:  Int J Cardiovasc Imaging       Date:  2017-10-25       Impact factor: 2.357

5.  Left ventricular chamber dilatation in hypertrophic cardiomyopathy: related variables and prognosis in patients with medical and surgical therapy.

Authors:  C Seiler; R Jenni; G Vassalli; M Turina; O M Hess
Journal:  Br Heart J       Date:  1995-11

6.  Is I-123-beta-methyl-p-iodophenyl-methylpentadecanoic acid imaging useful to evaluate asymptomatic patients with hypertrophic cardiomyopathy? I-123 BMIPP imaging to evaluate asymptomatic hypertrophic cardiomyopathy.

Authors:  Michihiro Narita; Tadashi Kurihara
Journal:  Int J Cardiovasc Imaging       Date:  2003-12       Impact factor: 2.357

7.  Clinical Characteristics and Prognosis of End-stage Hypertrophic Cardiomyopathy.

Authors:  Yan Xiao; Kun-Qi Yang; Yan-Kun Yang; Ya-Xin Liu; Tao Tian; Lei Song; Xiong-Jing Jiang; Xian-Liang Zhou
Journal:  Chin Med J (Engl)       Date:  2015-06-05       Impact factor: 2.628

8.  Morphological and Electrical Characteristics in Patient with Hypertrophic Cardiomyopathy: Quantitative Analysis of 864 Korean Cohort.

Authors:  Sung-Hwan Kim; Yong-Seog Oh; Gi-Byoung Nam; Kee-Joon Choi; Dae Hee Kim; Jong-Min Song; Duk-Hyun Kang; Jae-Kwan Song; You-Ho Kim
Journal:  Yonsei Med J       Date:  2015-11       Impact factor: 2.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.